Last reviewed 2026-05-28 · How we verify

Sulforadex

Evgen Pharma · Phase 1 active Small molecule ✓ Verified May 2026

Sulforadex is a Small molecule drug developed by Evgen Pharma. It is currently in Phase 1 development. Also known as: Stabilised sulforaphane.

Sulforadex is being studied as a potential treatment for Subarachnoid Hemorrhage, Prostate Cancer, Prostate Cancer, and Breast Neoplasm. It is being compared to a placebo in clinical trials, with the study identifier NCT02614742 registered on ClinicalTrials.gov.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Sulforadex
Also known as	Stabilised sulforaphane
Sponsor	Evgen Pharma
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

SFX-01 After Subarachnoid Haemorrhage (PHASE2)
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer (PHASE2)
Sulforadex in Healthy Human Males MAD (PHASE1)
Sulforadex in Healthy Volunteers SAD (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sulforadex CI brief — competitive landscape report
Sulforadex updates RSS · CI watch RSS
Evgen Pharma portfolio CI

Frequently asked questions about Sulforadex

What is Sulforadex?

Sulforadex is a Small molecule drug developed by Evgen Pharma.

Who makes Sulforadex?

Sulforadex is developed by Evgen Pharma (see full Evgen Pharma pipeline at /company/evgen-pharma).

Is Sulforadex also known as anything else?

Sulforadex is also known as Stabilised sulforaphane.

What development phase is Sulforadex in?

Sulforadex is in Phase 1.

Manufacturer: Evgen Pharma — full pipeline
Therapeutic area: All drugs in Other
Also known as: Stabilised sulforaphane

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing